Metraipolis › archive › dc_2f6957561735
Acquired EML4-ALK fusion and BRAF V600G dual bypass activation following osimertinib resistance in lung adenocarcinoma and successful treatment with… — Europe PMC PMID:42656778
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42656778
- DOI
- 10.3389/fonc.2026.1919298
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-16T20:38:31.727Z
- SHA-256 of the archived text
f44293f04bbc3c42993823262d5643b63dd5d1e7683d26aeead7d23046866c06- Stable URL of this page
https://metraipolis.com/documento/dc_2f6957561735
How to cite
Acquired EML4-ALK fusion and BRAF V600G dual bypass activation following osimertinib resistance in lung adenocarcinoma and successful treatment with… — Europe PMC PMID:42656778 — Europe PMC (en), https://europepmc.org/article/MED/42656778 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2f6957561735 (Metraipolis archive dc_2f6957561735, sha256 f44293f04bbc3c42993823262d5643b63dd5d1e7683d26aeead7d23046866c06)
BibTeX
@misc{dc2f6957561735,
title = {Acquired EML4-ALK fusion and BRAF V600G dual bypass activation following osimertinib resistance in lung adenocarcinoma and successful treatment with… — Europe PMC PMID:42656778},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42656778},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2f6957561735; sha256 f44293f04bbc3c42993823262d5643b63dd5d1e7683d26aeead7d23046866c06},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42656778. Agents can read the archived copy with the MCP tool read_document.